Use of stimulants in operational settings: Issues and considerations

Nicholas Davenport, Cheryl Lowry, Brian Pinkston

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

One of the first duties of the Physician is to educate the masses not to take medicine. Sir William Osler [1] Introduction Use of stimulants in clinical settings is guided by medicine, science, and the goal of benefiting patients with defined illnesses that are known to be responsive to stimulants (e.g., narcolepsy, attention deficit hyperactivity disorder, and shift work sleep disorder – the latter is discussed in Chapter 8, this volume). At the present time, legitimate use of stimulants (specifically, the amphetamines and modafinil) in operational settings in otherwise normal, healthy adults for management of fatigue is limited to the military – and, in particular, the United States Department of Defense (DoD) [2]. Currently within the US DoD, stimulants are approved for use only under restricted circumstances in certain sectors of aviation and in some Special Forces units. In this chapter we explore some of the experience and issues surrounding this use. The definition of “fatigue” is an issue in itself, the scope of which is beyond this chapter. The DoD uses the Human Factors Analysis and Classification System (DoD HFACS) to determine causal factors associated with accidents and mishaps [3]. DoD HFACS defines fatigue as an adverse physiological state in which: the individual's diminished physical or mental capability is due to an inadequate recovery, as a result of restricted or shortened sleep or physical or mental activity during prolonged wakefulness. Fatigue may additionally be described as acute, cumulative or chronic. DoD HFACS also recognizes the contribution of circadian rhythms to degraded performance: Circadian rhythm desynchrony is a factor when the individual's normal, 24-hour rhythmic biological cycle (circadian rhythm) is disturbed and it degrades task performance. This is caused typically by night work or rapid movement (such as one time zone per hour) across several time zones. Referred to as “shift lag” and “jet lag.” (Time in the new time zone will lead to adaptation and recovery; the amount of time depends on the number of time zones crossed and the direction of travel. Recovery from shift lag may never occur.) Throughout this chapter, we use “fatigue” to mean degraded cognitive/mental performance resulting from inadequate sleep, with or without circadian rhythm desynchrony.

Original languageEnglish (US)
Title of host publicationSleep Deprivation, Stimulant Medications, and Cognition
PublisherCambridge University Press
Pages237-256
Number of pages20
ISBN (Electronic)9780511783005
ISBN (Print)9781107004092
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Fatigue
Circadian Rhythm
United States Department of Defense
Sleep
Circadian Rhythm Sleep Disorders
Medicine
Amphetamines
Narcolepsy
Aviation
Wakefulness
Task Performance and Analysis
Attention Deficit Disorder with Hyperactivity
Statistical Factor Analysis
Accidents
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Davenport, N., Lowry, C., & Pinkston, B. (2012). Use of stimulants in operational settings: Issues and considerations. In Sleep Deprivation, Stimulant Medications, and Cognition (pp. 237-256). Cambridge University Press. https://doi.org/10.1017/CBO9780511783005.019

Use of stimulants in operational settings : Issues and considerations. / Davenport, Nicholas; Lowry, Cheryl; Pinkston, Brian.

Sleep Deprivation, Stimulant Medications, and Cognition. Cambridge University Press, 2012. p. 237-256.

Research output: Chapter in Book/Report/Conference proceedingChapter

Davenport, N, Lowry, C & Pinkston, B 2012, Use of stimulants in operational settings: Issues and considerations. in Sleep Deprivation, Stimulant Medications, and Cognition. Cambridge University Press, pp. 237-256. https://doi.org/10.1017/CBO9780511783005.019
Davenport N, Lowry C, Pinkston B. Use of stimulants in operational settings: Issues and considerations. In Sleep Deprivation, Stimulant Medications, and Cognition. Cambridge University Press. 2012. p. 237-256 https://doi.org/10.1017/CBO9780511783005.019
Davenport, Nicholas ; Lowry, Cheryl ; Pinkston, Brian. / Use of stimulants in operational settings : Issues and considerations. Sleep Deprivation, Stimulant Medications, and Cognition. Cambridge University Press, 2012. pp. 237-256
@inbook{1ea4e747fe5349cba6c571548ff61cf9,
title = "Use of stimulants in operational settings: Issues and considerations",
abstract = "One of the first duties of the Physician is to educate the masses not to take medicine. Sir William Osler [1] Introduction Use of stimulants in clinical settings is guided by medicine, science, and the goal of benefiting patients with defined illnesses that are known to be responsive to stimulants (e.g., narcolepsy, attention deficit hyperactivity disorder, and shift work sleep disorder – the latter is discussed in Chapter 8, this volume). At the present time, legitimate use of stimulants (specifically, the amphetamines and modafinil) in operational settings in otherwise normal, healthy adults for management of fatigue is limited to the military – and, in particular, the United States Department of Defense (DoD) [2]. Currently within the US DoD, stimulants are approved for use only under restricted circumstances in certain sectors of aviation and in some Special Forces units. In this chapter we explore some of the experience and issues surrounding this use. The definition of “fatigue” is an issue in itself, the scope of which is beyond this chapter. The DoD uses the Human Factors Analysis and Classification System (DoD HFACS) to determine causal factors associated with accidents and mishaps [3]. DoD HFACS defines fatigue as an adverse physiological state in which: the individual's diminished physical or mental capability is due to an inadequate recovery, as a result of restricted or shortened sleep or physical or mental activity during prolonged wakefulness. Fatigue may additionally be described as acute, cumulative or chronic. DoD HFACS also recognizes the contribution of circadian rhythms to degraded performance: Circadian rhythm desynchrony is a factor when the individual's normal, 24-hour rhythmic biological cycle (circadian rhythm) is disturbed and it degrades task performance. This is caused typically by night work or rapid movement (such as one time zone per hour) across several time zones. Referred to as “shift lag” and “jet lag.” (Time in the new time zone will lead to adaptation and recovery; the amount of time depends on the number of time zones crossed and the direction of travel. Recovery from shift lag may never occur.) Throughout this chapter, we use “fatigue” to mean degraded cognitive/mental performance resulting from inadequate sleep, with or without circadian rhythm desynchrony.",
author = "Nicholas Davenport and Cheryl Lowry and Brian Pinkston",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9780511783005.019",
language = "English (US)",
isbn = "9781107004092",
pages = "237--256",
booktitle = "Sleep Deprivation, Stimulant Medications, and Cognition",
publisher = "Cambridge University Press",
address = "United States",

}

TY - CHAP

T1 - Use of stimulants in operational settings

T2 - Issues and considerations

AU - Davenport, Nicholas

AU - Lowry, Cheryl

AU - Pinkston, Brian

PY - 2012/1/1

Y1 - 2012/1/1

N2 - One of the first duties of the Physician is to educate the masses not to take medicine. Sir William Osler [1] Introduction Use of stimulants in clinical settings is guided by medicine, science, and the goal of benefiting patients with defined illnesses that are known to be responsive to stimulants (e.g., narcolepsy, attention deficit hyperactivity disorder, and shift work sleep disorder – the latter is discussed in Chapter 8, this volume). At the present time, legitimate use of stimulants (specifically, the amphetamines and modafinil) in operational settings in otherwise normal, healthy adults for management of fatigue is limited to the military – and, in particular, the United States Department of Defense (DoD) [2]. Currently within the US DoD, stimulants are approved for use only under restricted circumstances in certain sectors of aviation and in some Special Forces units. In this chapter we explore some of the experience and issues surrounding this use. The definition of “fatigue” is an issue in itself, the scope of which is beyond this chapter. The DoD uses the Human Factors Analysis and Classification System (DoD HFACS) to determine causal factors associated with accidents and mishaps [3]. DoD HFACS defines fatigue as an adverse physiological state in which: the individual's diminished physical or mental capability is due to an inadequate recovery, as a result of restricted or shortened sleep or physical or mental activity during prolonged wakefulness. Fatigue may additionally be described as acute, cumulative or chronic. DoD HFACS also recognizes the contribution of circadian rhythms to degraded performance: Circadian rhythm desynchrony is a factor when the individual's normal, 24-hour rhythmic biological cycle (circadian rhythm) is disturbed and it degrades task performance. This is caused typically by night work or rapid movement (such as one time zone per hour) across several time zones. Referred to as “shift lag” and “jet lag.” (Time in the new time zone will lead to adaptation and recovery; the amount of time depends on the number of time zones crossed and the direction of travel. Recovery from shift lag may never occur.) Throughout this chapter, we use “fatigue” to mean degraded cognitive/mental performance resulting from inadequate sleep, with or without circadian rhythm desynchrony.

AB - One of the first duties of the Physician is to educate the masses not to take medicine. Sir William Osler [1] Introduction Use of stimulants in clinical settings is guided by medicine, science, and the goal of benefiting patients with defined illnesses that are known to be responsive to stimulants (e.g., narcolepsy, attention deficit hyperactivity disorder, and shift work sleep disorder – the latter is discussed in Chapter 8, this volume). At the present time, legitimate use of stimulants (specifically, the amphetamines and modafinil) in operational settings in otherwise normal, healthy adults for management of fatigue is limited to the military – and, in particular, the United States Department of Defense (DoD) [2]. Currently within the US DoD, stimulants are approved for use only under restricted circumstances in certain sectors of aviation and in some Special Forces units. In this chapter we explore some of the experience and issues surrounding this use. The definition of “fatigue” is an issue in itself, the scope of which is beyond this chapter. The DoD uses the Human Factors Analysis and Classification System (DoD HFACS) to determine causal factors associated with accidents and mishaps [3]. DoD HFACS defines fatigue as an adverse physiological state in which: the individual's diminished physical or mental capability is due to an inadequate recovery, as a result of restricted or shortened sleep or physical or mental activity during prolonged wakefulness. Fatigue may additionally be described as acute, cumulative or chronic. DoD HFACS also recognizes the contribution of circadian rhythms to degraded performance: Circadian rhythm desynchrony is a factor when the individual's normal, 24-hour rhythmic biological cycle (circadian rhythm) is disturbed and it degrades task performance. This is caused typically by night work or rapid movement (such as one time zone per hour) across several time zones. Referred to as “shift lag” and “jet lag.” (Time in the new time zone will lead to adaptation and recovery; the amount of time depends on the number of time zones crossed and the direction of travel. Recovery from shift lag may never occur.) Throughout this chapter, we use “fatigue” to mean degraded cognitive/mental performance resulting from inadequate sleep, with or without circadian rhythm desynchrony.

UR - http://www.scopus.com/inward/record.url?scp=84923491866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923491866&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511783005.019

DO - 10.1017/CBO9780511783005.019

M3 - Chapter

AN - SCOPUS:84923491866

SN - 9781107004092

SP - 237

EP - 256

BT - Sleep Deprivation, Stimulant Medications, and Cognition

PB - Cambridge University Press

ER -